179 related articles for article (PubMed ID: 32669430)
41. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.
Swart M; Kuipers H; Milder F; Jongeneelen M; Ritschel T; Tolboom J; Muchene L; van der Lubbe J; Izquierdo Gil A; Veldman D; Huizingh J; Verspuij J; Schmit-Tillemans S; Blokland S; de Man M; Roozendaal R; Fox CB; Schuitemaker H; Capelle M; Langedijk JPM; Zahn R; Brandenburg B
NPJ Vaccines; 2023 Nov; 8(1):176. PubMed ID: 37952003
[TBL] [Abstract][Full Text] [Related]
42. The immune response to influenza in older humans: beyond immune senescence.
McElhaney JE; Verschoor CP; Andrew MK; Haynes L; Kuchel GA; Pawelec G
Immun Ageing; 2020; 17():10. PubMed ID: 32399058
[TBL] [Abstract][Full Text] [Related]
43. Leveraging human immune organoids for rational vaccine design.
Kastenschmidt JM; Sureshchandra S; Wagar LE
Trends Immunol; 2023 Dec; 44(12):938-944. PubMed ID: 37940395
[TBL] [Abstract][Full Text] [Related]
44. Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine.
Chen GL; Subbarao K
Nat Med; 2009 Nov; 15(11):1251-2. PubMed ID: 19893556
[No Abstract] [Full Text] [Related]
45. Leveraging baseline transcriptional features and information from single-cell data to power the prediction of influenza vaccine response.
Ye X; Yang S; Tu J; Xu L; Wang Y; Chen H; Yu R; Huang P
Front Cell Infect Microbiol; 2024; 14():1243586. PubMed ID: 38384303
[TBL] [Abstract][Full Text] [Related]
46. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza.
Shibuya M; Tamiya S; Kawai A; Hirai T; Cragg MS; Yoshioka Y
iScience; 2021 Oct; 24(10):103131. PubMed ID: 34622175
[TBL] [Abstract][Full Text] [Related]
47. Sensitive NMR sensors detect antibodies to influenza.
Koh I; Hong R; Weissleder R; Josephson L
Angew Chem Int Ed Engl; 2008; 47(22):4119-21. PubMed ID: 18428168
[No Abstract] [Full Text] [Related]
48. Specific targeting of IL-1β activity to CD8
Van Den Eeckhout B; Van Hoecke L; Burg E; Van Lint S; Peelman F; Kley N; Uzé G; Saelens X; Tavernier J; Gerlo S
NPJ Vaccines; 2020; 5(1):64. PubMed ID: 32714571
[TBL] [Abstract][Full Text] [Related]
49. Microbiota licenses protective CD8
Tsankov BK; Philpott DJ
Nat Rev Immunol; 2024 Jul; ():. PubMed ID: 38965351
[No Abstract] [Full Text] [Related]
50. A Carbohydrate-Binding Protein from the Edible Lablab Beans Effectively Blocks the Infections of Influenza Viruses and SARS-CoV-2.
Liu YM; Shahed-Al-Mahmud M; Chen X; Chen TH; Liao KS; Lo JM; Wu YM; Ho MC; Wu CY; Wong CH; Jan JT; Ma C
Cell Rep; 2020 Aug; 32(6):108016. PubMed ID: 32755598
[TBL] [Abstract][Full Text] [Related]
51. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Stadlbauer D; Wilson PC; Aydillo T; Behzadi MA; Bhavsar D; Bliss C; Capuano C; Carreño JM; Chromikova V; Claeys C; Coughlan L; Freyn AW; Gast C; Javier A; Jiang K; Mariottini C; McMahon M; McNeal M; Solórzano A; Strohmeier S; Sun W; Van der Wielen M; Innis BL; García-Sastre A; Palese P; Krammer F
Nat Med; 2021 Jan; 27(1):106-114. PubMed ID: 33288923
[TBL] [Abstract][Full Text] [Related]
52. Synthetic Carbohydrate Chemistry and Translational Medicine.
Shivatare SS; Wong CH
J Org Chem; 2020 Dec; 85(24):15780-15800. PubMed ID: 33125238
[TBL] [Abstract][Full Text] [Related]
53. A selective drug delivery system based on phospholipid-type nanobubbles for lung cancer therapy.
Chan MH; Chan YC; Liu RS; Hsiao M
Nanomedicine (Lond); 2020 Nov; 15(27):2689-2705. PubMed ID: 33112189
[No Abstract] [Full Text] [Related]
54. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates.
Darricarrère N; Qiu Y; Kanekiyo M; Creanga A; Gillespie RA; Moin SM; Saleh J; Sancho J; Chou TH; Zhou Y; Zhang R; Dai S; Moody A; Saunders KO; Crank MC; Mascola JR; Graham BS; Wei CJ; Nabel GJ
Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658355
[TBL] [Abstract][Full Text] [Related]
55. Influenza virus neuraminidase regulates host CD8
Wu CY; Chuang HY; Wong CH
Commun Biol; 2020 Dec; 3(1):748. PubMed ID: 33293641
[TBL] [Abstract][Full Text] [Related]
56. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine.
Bullard BL; Weaver EA
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33805749
[TBL] [Abstract][Full Text] [Related]
57. An Update on Self-Amplifying mRNA Vaccine Development.
Blakney AK; Ip S; Geall AJ
Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33525396
[TBL] [Abstract][Full Text] [Related]
58. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
[TBL] [Abstract][Full Text] [Related]
59. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Zhou D; Duyvesteyn HME; Chen CP; Huang CG; Chen TH; Shih SR; Lin YC; Cheng CY; Cheng SH; Huang YC; Lin TY; Ma C; Huo J; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Donat RF; Godwin K; Buttigieg KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll MW; Gilbert-Jaramillo J; Knight ML; James W; Owens RJ; Naismith JH; Townsend AR; Fry EE; Zhao Y; Ren J; Stuart DI; Huang KA
Nat Struct Mol Biol; 2020 Oct; 27(10):950-958. PubMed ID: 32737466
[TBL] [Abstract][Full Text] [Related]
60. Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.
Giurgea LT; Morens DM; Taubenberger JK; Memoli MJ
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32718039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
